Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceChronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Virologic Tools for HCV Drug Resistance TestingChronic hepatitis C: This and the new era of treatmentFinally sofosbuvir: an oral anti-HCV drug with wide performance capabilityMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusNew virologic tools for management of chronic hepatitis B and CNeutralizing antibody response to hepatitis C virusDevelopment of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisionsToward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing AntibodyMolecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of ResistanceHepatitis C.HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsElucidation of hepatitis C virus transmission and early diversification by single genome sequencingNew preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replicationHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsHCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, BrazilRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsHepatitis C virus induces CD81 and claudin-1 endocytosis.Production, purification and characterization of recombinant, full-length human claudin-1.Frontiers in the treatment of hepatitis C virus infection.Direct-acting antiviral agents and the path to interferon independence.Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication.Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxinSafe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate modelRNA structural elements of hepatitis C virus controlling viral RNA translation and the implications for viral pathogenesis.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathwayClinical development of monoclonal antibody-based drugs in HIV and HCV diseasesMortality among British Columbians testing for hepatitis C antibody.Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry.Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Use of illumina deep sequencing technology to differentiate hepatitis C virus variants.
P2860
Q26740219-14251B15-65D7-4936-B2E6-B0E8C4536075Q26773585-6E3441C1-90E9-431E-8617-3BD834718D24Q26774374-A184468B-9DB5-4CED-9CFA-924CD4DF3872Q26775011-B2923E39-70D7-4452-80AB-CD76D5CD8D69Q26822400-059CCF6A-9CAD-4924-B56D-35B9DBEB2B6CQ26830190-097A0432-296E-4764-9EBA-25AA5F8333A2Q27026914-ADAD51E2-C031-443D-953A-DA208265DF84Q27027484-8F5BA3A4-F7ED-4866-BE61-6A7CC74FCC1BQ27468990-30B7C0A6-EB56-486A-8124-8BC0FE3B367FQ27673453-642377EC-DBFF-4354-8D99-285A3697BAA2Q27675615-926749C7-AFAD-4954-9038-1D42C3541404Q28084654-F7F6F398-D8ED-4F12-8848-B414A206E78AQ28481038-5960C54B-A28B-465F-AB4E-C3A475A6D8D1Q28482493-1460B19C-6C77-4D19-A45F-CF9769657AA0Q28536288-EE27006E-5DB9-4B54-B5C8-04E33F8D2AEEQ28538891-02DBA99A-9DBF-48DC-9CAB-A7CA6776C394Q28538943-9DEA53E9-EBC9-4E01-AD21-214F4F66B7D4Q28545971-EC9A397A-3241-4559-90A6-922913467783Q28552269-3260FDB4-5B64-4092-A3DC-A1D64473D596Q30512696-C7E9ED64-0658-44D6-85F8-38E064BCA7DFQ31118101-1CFAA889-8B28-4929-9F2D-B579E217B276Q33571517-B31E0251-6795-4837-866D-B0FA55347371Q33727347-33DDD7BD-F8D2-4CBF-9627-9DD38B161866Q33746198-978AE870-58D2-4CBB-954F-02F23472F2ABQ34168690-E20D55E6-2D1F-4EB1-BEED-D3C4320CE9BEQ34284247-4E061A3B-C106-47AF-A603-950DCEEB30C3Q34314871-64BFB5FC-9729-4D7D-8BFF-598FF8D00563Q34332546-F9B2A411-1265-4A4C-A05C-F354E972C911Q34369535-ED8139C0-FA5D-4762-A639-C1BA0DCB74BCQ34409751-CA4D30A2-D7F7-498D-ADB4-9AC9764F20E5Q34536782-C75E1F5F-5E76-4FC2-BCFE-17C981B46E1AQ34645221-32A062BB-828A-4AEF-A4A5-0B371CD7A215Q34806845-5BD8589B-09C4-4FD5-ADE3-E147824D19E2Q34908895-8655CC06-A4AA-413E-83FD-6F00BDC44FA3Q34983102-3507249F-D2E6-4251-A7EC-1B08278C8DBFQ35650866-0461A8A5-84E7-4301-8FB3-37008BDE78C2Q35685732-CFE66972-F981-4716-9B2E-C6DB93A372CDQ35699612-16E32A4F-7AEE-4B89-A0DC-C6173F264177Q35774186-A3B91EBA-08EC-4BAD-91D4-F2215B9AA6DFQ35806939-6654FFDB-651A-4ED8-B0D4-D163C8D05E29
P2860
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment failure and resistan ...... ugs against hepatitis C virus.
@en
Treatment failure and resistan ...... ugs against hepatitis C virus.
@nl
type
label
Treatment failure and resistan ...... ugs against hepatitis C virus.
@en
Treatment failure and resistan ...... ugs against hepatitis C virus.
@nl
prefLabel
Treatment failure and resistan ...... ugs against hepatitis C virus.
@en
Treatment failure and resistan ...... ugs against hepatitis C virus.
@nl
P356
P1433
P1476
Treatment failure and resistan ...... ugs against hepatitis C virus.
@en
P2093
Jean-Michel Pawlotsky
P304
P356
10.1002/HEP.24262
P407
P577
2011-05-01T00:00:00Z